Article Text

Download PDFPDF

Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma
  1. Peter G. Rose, MD,
  2. Haider Mahdi, MD, MPH,
  3. Amelia Jernigan, MD and
  4. Bin Yang, MD, PhD
  1. * Division of Gynecologic Oncology, Cleveland Clinic;
  2. Division of Gynecologic Oncology, MetroHealth Medical Center; and
  3. Department of Molecular Pathology, Cleveland Clinic, Cleveland, OH.
  1. Address correspondence and reprint requests to Peter G. Rose, MD, Cleveland Clinic Health System, 9500 Euclid Ave, Cleveland, OH 44195. E-mail: rosep{at}


Objectives The aim of this study was to evaluate the antitumor activity of bevacizumab in low-grade serous ovarian carcinoma (LGSOC).

Methods We retrospectively identified patients with LGSOC treated with bevacizumab.

Results Twelve patients with LGSOC who received bevacizumab were identified. Eleven patients received bevacizumab alone. Only 1 (8.3%) of 12 patients had evidence of a partial response. Ten (90.9%) of the 11 patients were progression free at 6 months. All but 1 patient who received only 2 courses before treatment interruption had a progression-free survival (PFS) of greater than 6 months. The median PFS was 48 months (range, 5–123+ months). Three of the patients reported in this series had extended disease stabilization that lasted for 123+, 48, and 15+ months after progression-free intervals on prior chemotherapy regimens of 2.5, 4, and 7 months, respectively. The median overall survival was not reached at a median follow-up of 32 months, with only 1 of the 12 patients dying of disease.

Conclusions In our series, in patients with LGSOC treated primarily with bevacizumab, primarily as a single agent, a low response rate but very long PFS is observed. In addition, patients have had secondary PFS durations that exceeded their prior PFS, which is a sign of anticancer activity.

  • Low-grade serous ovarian cancer
  • Bevacizumab

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.